← Back to Search

Other

HMPL-689 for Lymphoma

Phase 1

Waitlist Available

Led By Nilanjan Ghosh, MD

Research Sponsored by Hutchison Medipharma Limited

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)

Awards & highlights

Study Summary

This trial is testing a new drug, HMPL-689, to see if it is safe and effective in treating patients with relapsed or refractory lymphomas.

Who is the study for?

This trial is for patients with certain types of lymphoma that have relapsed or are not responding to standard treatments. Participants should be in relatively good physical condition (ECOG status 0 or 1) and expected to live more than 24 weeks. They must not have severe organ dysfunction, recent major surgery, heart issues like congestive heart failure, a history of significant liver disease, or any other condition that could interfere with the study.Check my eligibility

What is being tested?

The trial is testing HMPL-689's safety and how it's processed by the body in those with specific lymphomas that haven't responded well to other treatments. It's an open-label study where everyone knows what treatment they're getting, starting with small doses that increase over time.See study design

What are the potential side effects?

While specific side effects for HMPL-689 aren't listed here, common ones for cancer drugs include nausea, fatigue, risk of infection due to low blood cell counts, liver problems which might show up as yellowing skin or eyes (jaundice), and potential heart rhythm issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of adverse events as evaluated by the NCI CTCAE v5.0 grade

Secondary outcome measures

Area under the concentration-time curve in a selected time interval (AUC0-t)

Objective response rate (ORR) defined as the proportion of patients who have a CR or PR

maximum plasma concentration (Cmax)

Trial Design

1Treatment groups

Experimental Treatment

Group I: TreatmentExperimental Treatment1 Intervention

All patients take HMPL-689 taken daily

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

HMPL-689

2017

Completed Phase 1

~250

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Hutchison Medipharma LimitedLead Sponsor

100 Previous Clinical Trials

13,496 Total Patients Enrolled

7 Trials studying Lymphoma

677 Patients Enrolled for Lymphoma

HutchmedLead Sponsor

27 Previous Clinical Trials

5,293 Total Patients Enrolled

4 Trials studying Lymphoma

293 Patients Enrolled for Lymphoma

Nilanjan Ghosh, MDPrincipal InvestigatorAtrium Health Levine Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What have been the reported effects of taking HMPL-689 on patients?

"Due to minimal data pointing towards HMPL-689's efficacy and safety, it has been rated a 1 on our team's scale. This is reflective of the fact that this medication is still in its initial phase of testing."

Answered by AI

Are there still openings for participation in this clinical investigation?

"Affirmative. Clinicaltrials.gov shows that this clinical trial, which was initiated on August 26th 2019, is currently recruiting patients. 270 individuals are needed across 13 medical sites for the study to be completed successfully."

Answered by AI

How many individuals can partake in this clinical research concurrently?

"In order to successfully complete this medical trial, 270 participants will need to be enrolled. Those who meet the requirements may participate in various locations including Rogers' Highlands Oncology Group and both Mays Cancer Center and MD Anderson's Cancer Center in San Antonio, California."

Answered by AI

At how many sites is this clinical investigation being conducted?

"This clinical trail is being offered at 13 distinct institutions, including Highlands Oncology Group in Rogers, Mays Cancer Center and UT Health San Antonio. In addition to these locations, there are 10 other medical centres providing the same service such as MD Anderson Cancer Centre in San Antonio and Pacific Cancer Medical Centre in Anaheim."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

2019. "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03786926.

All > Lymphoma